Dalteparin: An update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease

Drugs

Volumn 60, Issue 1, 2000, Pages 203-237

  Dunn, C J ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; LIPID; NADROPARIN; PENTOSAN POLYSULFATE; WARFARIN;

ACUTE DISEASE; BLEEDING; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; HEART INFARCTION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; LIPID BLOOD LEVEL; OUTPATIENT CARE; PREGNANCY COMPLICATION; PROPHYLAXIS; REVIEW; THROMBOEMBOLISM;

EID: 0033867836     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060010-00010     Document Type: Review

References (157)

1. Unfractionated and low-molecular-weight heparin: Comparisons and current recommendations
2. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
3. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders
4. Low-molecular-weight heparin
5. Dalteparin Sodium
6. Fragmin Ampoules
7. Heparin and its low molecular weight derivatives: Anticoagulant and antithrombotic properties
8. An international standard for low molecular weight heparin
9. Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis
10. Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin(R)) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin)
11. The influence of surgical trauma on factor XaI and IIaI activity and heparin concentration after a single dose of low-molecular-weight heparin
12. Comparative biological modifications induced by 3 low molecular weight heparins, PK 10169, Kabi 2165 and CY 216 and a non-fractionated heparin, injected subcutaneously in healthy volunteers, general surgery patients and elderly patients with medical disorders
13. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers
14. Heparin and fibrinolysis - comparison of subcutaneous administration of unfractionated and low molecular weight heparin
15. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement
16. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin)
17. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin(R)) in stroke patients
18. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis
19. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial
20. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin
21. Prospective double-blind comparison between Fragmin and conventional low-dose heparin: Thromboprophylactic effect and bleeding complications
22. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration
23. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)
24. The heparin-mobilisable pool of platelet factor 4: A comparison of intravenous and subcutaneous heparin and Kabi heparin fragment 2165
25. Postoperative activation of the haemostatic system - Influence of prolonged thromboprophylaxis in patients undergoing total hip arthroplasty
26. Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man
27. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease
28. Lipolytic effect of low-molecular-weight-heparin (Fragmin(R)) and heparin/dihydroergotamine in thromboprophylactic doses during total hip replacement
29. Low-molecular-weight heparin (LMWH): Influence on blood lipids in patients on chronic haemodialysis
30. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin)
31. Plasma lipolytic activity after subcutaneous administration of heparin and a low molecular weight heparin fragment
32. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin
33. The influence of low molecular weight heparin on blood lipoproteins in patients on chronic hemodialysis [abstract]
34. Low molecular weight heparin versus standard heparin in patients with hypertriglyceridemia on hemodialysis - 5 years follow-up [abstract]
35. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment
36. Low molecular weight heparin (Kabi 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers
37. Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations
38. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)
39. Pharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjects
40. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance
41. Erythrocyte adhesion affects the bioavailability of low-molecular-weight heparin [abstract]
42. A crossover comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan
43. Effect of ketorolac and low molecular weight heparin individually and in combination on haemostasis
44. Modern aspects of prophylaxis and therapy for venous thrombo-embolic disease
45. Risk of and prophylaxis for venous thromboembolism in hospital patients
46. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations
47. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
48. Physiological changes due to age: Implications for the prevention and treatment of thrombosis in older patients
49. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis
50. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement
51. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin
52. A double-blind randomized comparison of low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery [abstract]
53. A double-blind, randomized comparison of low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital versus warfarin-placebo in hiparthroplasty patients [abstract]
54. Prolonged thromboprophylaxis following hip replacement surgery - Results of double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
55. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study
56. Prophylaxis of thromboembolism in general surgery: Comparison between standard heparin and Fragmin
57. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery
58. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery
59. Comparison of pentosan polysulfate sodium (Na-PPS) with a low-molecular-weight heparin in the prevention of venous thrombosis after abdominal surgery
60. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin
61. A multicentre, randomised, assessor-blind, pilot study comparing the efficacy in the prophylaxis of DVT and the safety of Orgaran (Org 10172), Fragmin, Clexane/Lovenox in patients undergoing surgery for a fractured hip [abstract]
62. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies
63. Thromboprophylaxis with low molecular weight heparin (Dalteparin) in pregnancy
64. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy - A longitudinal safety study
65. Long-term thromboprophylaxis with low-molecular-weight-heparin (dalteparin) in high-risk pregnancies [abstract]
66. Low-molecular-weight heparins in the treatment of pulmonary embolism
67. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy
68. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study
69. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis
70. Deep vein thrombosis treatment. A comparative study: Subcutaneous Fragmin versus unfractionated heparin administered by continuous infusion. Multicenter trial
71. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep vein thrombosis (DVT)
72. Subcutaneous heparin treatment of deep vein thrombosis: A comparison of unfactionated and low molecular weight heparin
73. Comparison of once-daily subcutaneous Fragmin(R) with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
74. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
75. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
76. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open randomized pilot study
77. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis
78. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: A retrospective analysis
79. Low molecular weight heparins in the outpatient management of venous thromboembolism
80. Outpatient therapy with low-molecular-weight heparins: New perspectives for treatment of deep vein thrombosis
81. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group
82. Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity
83. Outpatient treatment of pulmonary embolism with dalteparin
84. Dalteparin for deep venous thrombosis: A hospital-in-the-home program
85. Outpatient treatment of deep vein thrombosis and pulmonary embolism: A hospital-based program
86. Long term follow up of patients with deep vein thrombosis treated in an outpatient setting
87. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection
88. Long-term outpatient dalteparin (Fragmin) therapy for arterial and venous thrombosis: Efficacy and safety - A preliminary report
89. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial
90. Management strategies for a better outcome in unstable coronary artery disease
91. Low molecular weight heparins: Promising therapy for unstable angina and non-Q wave myocardial infarction
92. A comparison of aspirin plus tirofiban with aspirin plus hep heparin for unstable angina
93. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
94. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
95. Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
96. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
97. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis
98. Reactivation of unstable angina after the discontinuation of heparin
99. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
100. Low-molecular-weight heparin during instability in coronary artery disease
101. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
102. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection
103. Long term treatment with low molecular weight heparin (dalteparin) reduces cardiac events in unstable coronary artery disease with troponin-T elevation: A FRISCII substudy
104. Diagnosis and management of patients with unstable angina
105. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
106. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction - A pilot study: Bio-chemical markers in acute coronary syndromes (BIOMACS II)
107. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
108. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study
109. Multicentre randomised prospective trial of LMWH (Dalteparin sodium - Fragmin(R)) in acute myocardial infarction
110. Anticoagulants and extracorporeal circuits
111. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: Prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin
112. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: A randomized cross-over study
113. The adequacy of Fragmin as a single bolus dose with reused dialyzers
114. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis
115. Clinical application of Fragmin (FR-860) in hemodialysis: Multicenter cooperative study in Japan
116. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration
117. A comparison of low molecular weight heparin with unfractionated heparin for anticoagulation during hemodialysis
118. First randomized longterm comparative clinical trial for efficacy and safety of two LMWH in hemodialysis: Tinzaparin versus dalteparin
119. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venvenous hemofiltration: A double-blind, randomized, crossover study
120. Lancet
121. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients
122. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study
123. Low molecular weight versus unfractionated heparin: A clinical and economic appraisal
124. An economic assessment of dalteparin versus warfarin in total hip replacement
125. Outpatient DVT treatment with Fragmin(R) can result in cost and bed savings
126. Evaluacion economica del uso de dalteparina sodica versus heparina no fraccionada en el tratamiento de la trombosis venosa profunda
127. A pharmacoeconomic evaluation of low-molecular-weight heparin in patients after total hip-replacement surgery
128. The cost of unfractionated and low-molecular weight heparin in the management of acute coronary syndromes
129. Dalteparin sodium
130. Transfer of low molecular heparin during breast feeding
131. Heparins, coumarin, and bone density
132. Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin
133. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?
134. Heparin-associated thrombocytopenia: The antibody is not heparin specific
135. Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution
136. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
137. In-vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets
138. Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes
139. Lack of in vitro cross-reactivity predicts safety of low-molecular weight heparins in heparin-induced thrombocytopenia
140. Are symptomatic endpoints acceptable in thromboprophylactic studies?
141. How 'gold' is the standard? Interobservers' variation on venograms
142. The optimum duration of low molecular weight heparin for thromboembolism prevention in high risk orthopedic surgery
143. Applying risk assessment models in orthopaedic surgery: Overview of our clinical experience
144. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
145. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
146. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
147. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
148. Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation?
149. Safety of low-molecular-weight heparin in pregnancy: A systematic review
150. Low-molecular-weight heparins in pregnancy
151. Unstable angina: A review and practical guide to management
152. Antithrombotic agents in coronary artery disease
153. Atrial fibrillation and stroke: Prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project)